Martin is Vice President of Corporate Development Assessments at Bristol Myers Squibb. In this role, he works to strengthen the company’s assessments of meaningful M&A opportunities across BMS Therapeutic Areas and into expansion areas. Prior to this role, Martin served as the Head of Oncology Search & Evaluation in the Oncology Business Development Unit at Bristol Myers Squibb, where he led a team performing global scouting and diligence activities for therapeutic opportunities to treat solid tumors.

Prior to joining BMS Martin led drug discovery teams at Merck Research Laboratories to discover and develop novel pharmaceutical therapies across multiple therapeutic areas from 2005-2012. In 2012, Martin joined Daiichi Sankyo to find business development opportunities and subsequently joined Bristol Myers Squibb Business Development in 2015.

Martin received his B.Sc. Hons. from Lancaster University in 1995, a M(Res)Sc in Immunology and Oncology from University of Birmingham in 1996 and his Ph.D. in cardiovascular disease from the University of Bristol in 2000. Martin then went on to receive his postdoctoral training in Dr. Elizabeth Nabel’s Vascular Biology Branch of the National Heart Lung and Blood Institute (NIH) in Bethesda, Maryland.